Journal article · 2022

Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.

Medhavi Gupta, Othman Salim Akhtar, Bhavyaa Bahl, Angel Mier-Hicks, Kristopher M. Attwood, Kayla Catalfamo, Bishal Gyawali, Pallawi Torka

Journal of Clinical Oncology, 40(16_suppl), 6519 · Published 1 June 2022 · DOI 10.1200/jco.2022.40.16_suppl.6519

View at the publisherCite this paper

In brief

“Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.” is a 2022 journal article by Medhavi Gupta and 7 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 1 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2024 (1)
Authors
8

Abstract

6519 Background: HRQoL data in cancer clinical trials can inform tolerability of new drugs, facilitate informed decision-making, and influence health care and policy decisions, but are frequently underreported. We reviewed all registration trials that informed Food and Drug Administration (FDA) approval between 2015-2020 for latency and quality of HRQoL reporting. Methods: HRQoL data for each… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gupta, M., Akhtar, O. S., Bahl, B., Mier-Hicks, A., Attwood, K. M., Catalfamo, K., Gyawali, B., & Torka, P. (2022). Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals. Journal of Clinical Oncology, 40(16_suppl), 6519. https://doi.org/10.1200/jco.2022.40.16_suppl.6519

MLA 9

Gupta, Medhavi, et al. “Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.” Journal of Clinical Oncology, vol. 40, no. 16_suppl, 2022, p. 6519. https://doi.org/10.1200/jco.2022.40.16_suppl.6519.

Chicago

Gupta, Medhavi, Othman Salim Akhtar, Bhavyaa Bahl, Angel Mier-Hicks, Kristopher M. Attwood, Kayla Catalfamo, Bishal Gyawali, and Pallawi Torka. 2022. “Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.” Journal of Clinical Oncology 40 (16_suppl): 6519. https://doi.org/10.1200/jco.2022.40.16_suppl.6519.

Harvard

Gupta, M. et al. (2022) ‘Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.’, Journal of Clinical Oncology, 40(16_suppl), p. 6519. doi:10.1200/jco.2022.40.16_suppl.6519.

IEEE

M. Gupta et al., “Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.,” Journal of Clinical Oncology, vol. 40, no. 16_suppl, p. 6519, 2022, doi: 10.1200/jco.2022.40.16_suppl.6519.

BibTeX

@article{gupta2022health,
  title     = {{Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals.}},
  author    = {Gupta, Medhavi and Akhtar, Othman Salim and Bahl, Bhavyaa and Mier-Hicks, Angel and Attwood, Kristopher M. and Catalfamo, Kayla and Gyawali, Bishal and Torka, Pallawi},
  journal   = {Journal of Clinical Oncology},
  year      = {2022},
  volume    = {40},
  number    = {16_suppl},
  pages     = {6519},
  doi       = {10.1200/jco.2022.40.16_suppl.6519},
  url       = {https://doi.org/10.1200/jco.2022.40.16_suppl.6519}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • health-related quality of life
  • FDA drug approval
  • cancer clinical trials
  • hematology
  • solid tumors
  • clinical trial registration
  • time to publication
  • overall survival

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Gupta, M., Akhtar, O. S., Bahl, B., Mier-Hicks, A., Attwood, K. M., Catalfamo, K., Gyawali, B., & Torka, P. (2022). Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals. Journal of Clinical Oncology, 40(16_suppl), 6519. https://doi.org/10.1200/jco.2022.40.16_suppl.6519

How many times has this paper been cited?

1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Medhavi Gupta, Othman Salim Akhtar, Bhavyaa Bahl, Angel Mier-Hicks, Kristopher M. Attwood, Kayla Catalfamo, Bishal Gyawali, Pallawi Torka.

What is the DOI of this paper?

10.1200/jco.2022.40.16_suppl.6519, permanently at https://doi.org/10.1200/jco.2022.40.16_suppl.6519. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.